Home/Indications/Respiratory/Allergic Rhinitis

Allergic Rhinitis

Respiratory 1 original drugs

Novel Drugs

Reformulations

Drug Targets

Respiratory indication. Allergic Rhinitis has 1 FDA-approved novel treatment, led by AZURITY, with 37 active industry clinical trials across 4 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Allergic Rhinitis Market Leaders

Companies with the most FDA-approved novel Allergic Rhinitis drugs.

AZURITY

original drugs

Phase 3 Readouts Pro

4 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

HDM SLIT-tablet (12 SQ-HDM)

ALK-Abelló A/S

Estimated · fresh NCT07060885

Q3 2026

Experimental

Daewon Pharmaceutical Co., Ltd.

Estimated · aging NCT07168473

Q3 2026

LY3650150

Eli Lilly

Estimated · fresh NCT06339008

Unlock 1 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Allergic Rhinitis Treatments by Mechanism

Top 8 mechanisms across 20 industry trials with a known mechanism of action.

See full pipeline →

Glucocorticoid receptor

7 trials 7 sponsors

Beta-2 adrenergic receptor/Glucocorticoid receptor

3 trials 3 sponsors

H1-receptor

3 trials 2 sponsors

Corticosteroid

2 trials 2 sponsors

Anti-IgE

2 trials 2 sponsors

Glucocorticoid receptor/Histamine H1 receptor

1 trials 1 sponsor

Interleukin-4 Receptor alpha Antagonist

1 trials 1 sponsor

Nonsteroidal Anti-inflammatory Drug

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Allergic Rhinitis Clinical Pipeline by Phase

267 industry-sponsored trials across 116 sponsors

View full landscape →

Showing 20 of 20 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Viatris Inc.	Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate	—	NOT YET RECRUITING	2027-03	NCT07597473
MEDA Pharma GmbH & Co. KG	Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3	—	COMPLETED	2021-12-04	NCT04652245
Bayer	Loratadine (Claritin, BAY76-2211)	—	COMPLETED	2019-11-13	NCT04162795
MEDA Pharma GmbH & Co. KG	Azelastine hydrochloride + fluticasone propionate nasal spray	—	COMPLETED	2017-03-29	NCT03004131
ALK-Abelló A/S	Grazax	—	COMPLETED	2015-12	NCT01854736
Menarini International Operations Luxembourg SA	Bilastine	—	COMPLETED	2015-12	NCT02576041
Meda Pharmaceuticals	205.5 mcg of azelastine hydrochloride	—	COMPLETED	2014-04	NCT01880840
HAL Allergy	PURETHAL Birch, 20.000 AUM/ml	—	COMPLETED	2014-02	NCT01918956
Sumitomo Pharma America, Inc.	ciclesonide nasal aerosol	—	COMPLETED	2013-07	NCT01654536
Handok Inc.	Ciclesonide	Glucocorticoid receptor	COMPLETED	2012-07	NCT01430260
ORA, Inc.	Fluticasone Propionate Nasal Spray	—	COMPLETED	2011-10	NCT01439815
Reig Jofre Group	—	—	COMPLETED	2011-06	NCT01478425
Alcon Research	Olopatadine hydrochloride 0.6% nasal spray (PATANASE)	—	COMPLETED	2011-01	NCT00789555
HAL Allergy	PURETHAL Grasses, 20.000 AUM/ml	—	COMPLETED	2010-09	NCT01059266
Alcon Research	Olopatadine HCl Nasal Spray, 0.6%	—	COMPLETED	2009-05	NCT00845195
Alcon Research	Olopatadine HCL Nasal Spray, 0.6%	—	COMPLETED	2009-01	NCT00691665
Merck	loratadine	—	COMPLETED	2008-12	NCT00730912
Alcon Research	Olopatadine 0.6% / Azelastine 137 mcg	—	COMPLETED	2008-11	NCT00772304
UCB Pharma	levocetirizine dihydrochloride	—	COMPLETED	2008-07	NCT00653224
UCB Pharma	levocetirizine dihydrochloride	—	COMPLETED	2008-06	NCT00621959

Showing 100 of 117 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Daewon Pharmaceutical Co., Ltd.	Experimental	—	RECRUITING	2026-08-31	NCT07168473
Eli Lilly	LY3650150	—	RECRUITING	2026-09	NCT06339008
Genrix (Shanghai) Biopharmaceutical Co., Ltd.	GR1802 injection	—	RECRUITING	2026-04-30	NCT07154342
Shanghai Mabgeek Biotech.Co.Ltd	MG-K10 Humanized Monoclonal Antibody Injection	—	RECRUITING	2025-05-31	NCT06846385
Laboratorios Silanes S.A. de C.V.	Desloratadine / Betamethasone in fixed dose	—	RECRUITING	2025-05-11	NCT06916884
ALK-Abelló A/S	HDM SLIT-tablet (12 SQ-HDM)	—	ACTIVE NOT RECRUITING	2026-09-06	NCT07060885
Longbio Pharma	LP-003	—	ACTIVE NOT RECRUITING	2026-03-31	NCT07291284
Genrix (Shanghai) Biopharmaceutical Co., Ltd.	GR1802 injection	—	NOT YET RECRUITING	2027-05-15	NCT07199257
Prime Gene Therapeutics Co., Ltd.	PG-011 nasal spray 0.6%(twice daily)	—	NOT YET RECRUITING	2026-06-30	NCT07146126
Inmunotek S.L.	3,000 MM09	—	NOT YET RECRUITING	2026-06-01	NCT05641272
EMS	DEP114	—	NOT YET RECRUITING	2025-03-15	NCT06272409
Eurofarma Laboratorios S.A.	Desloratadine , Prednisolone	—	COMPLETED	2025-03-23	NCT05214911
Keymed Biosciences Co.Ltd	CM310	—	COMPLETED	2023-12-04	NCT05908032
Allergy Therapeutics	PQ Grass	—	COMPLETED	2023-11-01	NCT05540717
Novartis	Mometasone	—	COMPLETED	2023-06-20	NCT05311475
Novartis	—	—	COMPLETED	2023-06-14	NCT05590598
ALK-Abelló A/S	Sublingual allergy immunotherapy tablet	—	COMPLETED	2023-04-01	NCT04145219
Opella Healthcare Group SAS, a Sanofi Company	Fexofenadine	—	COMPLETED	2023-03-14	NCT05692154
Abdi Ibrahim Ilac San. ve Tic A.S.	AI201901	—	COMPLETED	2023-03-03	NCT04729517
ALK-Abelló A/S	HDM SLIT-tablet	—	COMPLETED	2022-05-18	NCT03654976
Regeneron	REGN5713	—	COMPLETED	2021-08-24	NCT04709575
ALK-Abelló A/S	HDM SLIT-tablet	—	COMPLETED	2021-04-24	NCT04541004
Bayer	Azelastine hydrochloride (BAYR9258)	—	COMPLETED	2021-03-17	NCT04264637
Libbs Farmacêutica LTDA	Fluticasone Propionate	Beta-2 adrenergic receptor/Glucocorticoid receptor	COMPLETED	2020-04-01	NCT04332978
MEDA Pharma GmbH & Co. KG	Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT	—	COMPLETED	2019-09-24	NCT03599791
Hanmi Pharmaceutical Company Limited	HCP1102	—	COMPLETED	2019-06-24	NCT04324918
Marinomed Biotech AG	Rhinocort	Corticosteroid [EPC]	COMPLETED	2019-04-05	NCT03755557
Glenmark Specialty S.A.	GSP 301 NS	—	COMPLETED	2018-11-14	NCT03463031
Leti Pharma GmbH	s.c. injection	—	COMPLETED	2018-07-30	NCT01694836
Novartis	Omalizumab	Anti-IgE [EPC]	COMPLETED	2018-05-11	NCT03369704
Glenmark Specialty S.A.	GSP 301 NS	—	COMPLETED	2017-07	NCT02709538
Hanlim Pharm. Co., Ltd.	HL151	—	COMPLETED	2017-02-20	NCT03655210
Glenmark Specialty S.A.	GSP 301 NS	—	COMPLETED	2017-01	NCT02870205
BioTech Tools S.A.	gpASIT+TM	—	COMPLETED	2016-08	NCT02560948
Glenmark Specialty S.A.	GSP 301 NS	—	COMPLETED	2016-07	NCT02631551
ALK-Abelló A/S	Grazax	—	COMPLETED	2015-09	NCT01061203
Hanmi Pharmaceutical Company Limited	HCP1102+HGP0711Placebo	—	COMPLETED	2015-07	NCT02552667
Organon and Co	Desloratadine 5 mg	—	COMPLETED	2015-04-27	NCT02320396
Abbott	Phleum pratense grass pollen allergen extract	—	COMPLETED	2015-03	NCT02245360
Padagis LLC	Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray	—	COMPLETED	2015-02	NCT02230696
Ahn-Gook Pharmaceuticals Co.,Ltd	AGR tablet	—	COMPLETED	2015-01	NCT01982916
AstraZeneca	Ciclesonide	Glucocorticoid receptor	COMPLETED	2014-10	NCT02155881
EMS	Dexchlorpheniramine + Betamethasone	—	COMPLETED	2014-10	NCT01529229
Amneal Pharmaceuticals, LLC	Mometasone Furoate Nasal Spray, 50 mcg	—	COMPLETED	2014-03	NCT02125253
Meda Pharmaceuticals	azelastine hydrochloride and fluticasone propionate	Glucocorticoid receptor/Histamine H1 receptor	COMPLETED	2014-02	NCT01915823
Organon and Co	Desloratadine 5 mg	—	COMPLETED	2014-01-26	NCT01918033
Organon and Co	Montelukast Oral Granules (OG)	—	COMPLETED	2013-12-24	NCT01852812
Tanabe Pharma Corporation	Bepotastine besilate	H1-receptor	COMPLETED	2013-12	NCT01861522
Actavis Inc.	Mometasone Nasal Spray	—	COMPLETED	2013-12	NCT01850823
Tanabe Pharma Corporation	Bepotastine besilate	H1-receptor	COMPLETED	2013-11	NCT01900054
Meda Pharmaceuticals	Dymista Nasal Spray	—	COMPLETED	2013-11	NCT01794741
Teva Branded Pharmaceutical Products R&D, Inc.	BDP Nasal Aerosol	—	COMPLETED	2013-10	NCT01783548
Organon and Co	Montelukast	—	COMPLETED	2013-09-01	NCT01857063
Nasaleze International Ltd	—	—	COMPLETED	2013-06	NCT03039816
Yuhan Corporation	Bilastine	—	COMPLETED	2013-06	NCT01400828
ALK-Abelló A/S	AVANZ olea	—	COMPLETED	2013-04	NCT01674595
Sumitomo Pharma America, Inc.	Ciclesonide nasal aerosol 37 mcg	—	COMPLETED	2013-03	NCT01458275
Eurofarma Laboratorios S.A.	Mometasone furoate	Glucocorticoid receptor	COMPLETED	2013-02	NCT01372865
Teva Branded Pharmaceutical Products R&D, Inc.	BDP	—	COMPLETED	2013-02	NCT01697956
GSK	Fluticasone propionate	Beta-2 adrenergic receptor/Glucocorticoid receptor	COMPLETED	2013-02	NCT01817790
Hanmi Pharmaceutical Company Limited	Montelukast + Levocetirizine	—	COMPLETED	2013-02	NCT01640535
Laboratorios Leti, S.L.	Allergen extract (Phleum pratense)	—	COMPLETED	2013-01	NCT00916422
Sumitomo Pharma America, Inc.	Ciclesonide nasal aerosol 37 mcg	—	COMPLETED	2012-12	NCT01451541
Organon and Co	Montelukast 10 mg/loratadine 10 mg	—	COMPLETED	2012-10-10	NCT01673620
Padagis LLC	Mometasone furoate	Glucocorticoid receptor	COMPLETED	2012-10	NCT01673659
InQpharm Group	—	—	COMPLETED	2012-09	NCT01503957
ALK-Abelló A/S	AVANZ MITE	—	COMPLETED	2012-07	NCT01568190
Stallergenes Greer	Birch pollen allergen extract	—	COMPLETED	2012-07	NCT01731249
Bayer	Phenylephrine HCl (Sinus Comfort, BAY112476)	—	COMPLETED	2012-06-06	NCT04534452
Azidus Brasil	Cloratadd-D	—	COMPLETED	2012-04	NCT01228630
Idorsia Pharmaceuticals Ltd.	ACT-129968	—	COMPLETED	2012-02	NCT01484119
ALK-Abelló A/S	Pangramin SLIT HDM mix.	—	COMPLETED	2012-02	NCT01603056
GenMont Biotech Incorporation	eN-Lac®	—	COMPLETED	2012-01	NCT01116778
Tanabe Pharma Corporation	TAU-284	—	COMPLETED	2011-12	NCT01425632
Hanlim Pharm. Co., Ltd.	mometasone furoate plus azelastine HCl	—	COMPLETED	2011-12	NCT01470053
Sumitomo Pharma America, Inc.	ciclesonide nasal aerosol	—	COMPLETED	2011-11	NCT01378429
Sumitomo Pharma America, Inc.	ciclesonide	Glucocorticoid receptor	COMPLETED	2011-11	NCT01401465
Bayer	Phenylephrine	—	COMPLETED	2011-10	NCT01413958
Apotex Inc.	Ciclesonide nasal spray, 50 μg per actuation.	—	COMPLETED	2011-08	NCT02273817
SamA Pharmaceutical Co., Ltd	CITUS Dry Syrup	—	COMPLETED	2011-08	NCT01539304
Teva Branded Pharmaceutical Products R&D, Inc.	BDP HFA	—	COMPLETED	2011-07	NCT01307319
Magna Pharmaceuticals, Inc.	STAHIST	—	COMPLETED	2011-06	NCT01293201
Sumitomo Pharma America, Inc.	ciclesonide hydrofluoroalkane (HFA) nasal aerosol	—	COMPLETED	2011-04	NCT01287364
Meda Pharmaceuticals	Azelastine hydrochloride nasal spray 0.15%	—	COMPLETED	2011-04	NCT01018862
Sumitomo Pharma America, Inc.	ciclesonide HFA 160 μg	—	COMPLETED	2010-11	NCT01067105
Teva Branded Pharmaceutical Products R&D, Inc.	Prednisone capsules	—	COMPLETED	2010-09	NCT01133626
GSK	fluticasone furoate nasal spray	—	COMPLETED	2010-05	NCT01231464
Sumitomo Pharma America, Inc.	Ciclesonide HFA Nasal Aerosol 320 mcg	—	COMPLETED	2010-05	NCT01033825
Teva Branded Pharmaceutical Products R&D, Inc.	Beclomethasone dipropionate	Glucocorticoid receptor	COMPLETED	2010-02-28	NCT01024608
Eurofarma Laboratorios S.A.	Noex	—	COMPLETED	2010-02	NCT01022047
Sumitomo Pharma America, Inc.	Ciclesonide HFA 160 μg	—	COMPLETED	2010-02	NCT01010971
Sumitomo Pharma America, Inc.	Ciclesonide HFA 80 mcg	—	COMPLETED	2010-01	NCT00953147
Clinical Research International Limited	Levocetirizine	—	COMPLETED	2010-01	NCT01000792
Bayer	Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg	—	COMPLETED	2009-11	NCT00976209
Roxall Medizin	Subcutaneous injections with highly polymerized allergen extract	—	COMPLETED	2009-11	NCT01012531
Stallergenes Greer	300 IR	—	COMPLETED	2009-08	NCT00955825
Meda Pharmaceuticals	azelastineHcl	—	COMPLETED	2009-07	NCT00883168
Organon and Co	Mometasone furoate nasal spray (MFNS)	—	COMPLETED	2009-05	NCT00599027
Sumitomo Pharma America, Inc.	80 mcg Ciclesonide	—	COMPLETED	2009-02	NCT00790023
Meda Pharmaceuticals	0.15% azelastine hydrochloride	—	COMPLETED	2009-02	NCT00824473

Showing 92 of 92 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.	TQH2722 injection	—	RECRUITING	2026-11	NCT07398859
Alixer Nexgen Therapeutics Limited	ALDP001 Nasal Spray	—	RECRUITING	2026-04	NCT07219849
Keymed Biosciences Co.Ltd	Stapokibart Injection	—	RECRUITING	2025-10-30	NCT06525597
Guangdong Hengrui Pharmaceutical Co., Ltd	SHR-1819 Injection	—	RECRUITING	2025-10	NCT07091357
Prime Gene Therapeutics Co., Ltd.	Pumecitinib Nasal Spray 0.3%	—	ACTIVE NOT RECRUITING	2025-05-15	NCT06837233
Genrix (Shanghai) Biopharmaceutical Co., Ltd.	GR1802 injection	—	ACTIVE NOT RECRUITING	2025-05	NCT06315426
Akeso	AK139	—	NOT YET RECRUITING	2026-09-30	NCT07436234
Chengdu Kangnuoxing Biopharma,Inc.	Stapokibart injection	—	NOT YET RECRUITING	2026-10	NCT07617324
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.	Sublingual Film for Dermatophagoides pteronyssinus	—	NOT YET RECRUITING	2027-06-01	NCT07475715
Jemincare	JYB1904	—	NOT YET RECRUITING	2027-10	NCT07459452
Inimmune Corporation	INI-2004	—	COMPLETED	2026-04-23	NCT07556393
RDC Clinical Pty Ltd	—	—	COMPLETED	2026-01-29	NCT06907680
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQC2938 injection	—	COMPLETED	2025-09-12	NCT07052097
Shanghai JunTop Biosciences Co., LTD	JT002 Nasal spray	—	COMPLETED	2025-05-06	NCT06861101
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.	TQH2722 injection	—	COMPLETED	2025-04-30	NCT06760182
MEDA Pharma GmbH & Co. KG	Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)	—	COMPLETED	2024-02-23	NCT06126952
Keymed Biosciences Co.Ltd	CM310	—	COMPLETED	2023-12-10	NCT05908721
Longbio Pharma	LP-003 dose 1	—	COMPLETED	2023-10-19	NCT06046391
Regeneron	REGN5713	—	COMPLETED	2023-07-31	NCT05430919
Revolo Biotherapeutics	IRL201104	—	COMPLETED	2023-03-27	NCT05098522
Anhui Palo Alto Pharmaceuticals, Inc.	PA9159 nasal spray solution, 10 μg once daily for 14 days	—	COMPLETED	2022-10-10	NCT05234580
AllerPops Corp	—	—	COMPLETED	2022-09-05	NCT05956691
Synmosa Biopharma Corp.	azelastine/fluticasone 137/50 mcg nasal spray	—	COMPLETED	2021-07-20	NCT06051786
Marinomed Biotech AG	Eye Drops, Solution in Single-Dose Container	—	COMPLETED	2021-05-27	NCT04532710
Humanis Saglık Anonim Sirketi	140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)	—	COMPLETED	2021-04-10	NCT04817800
Advagene Biopharma Co. Ltd.	AD17002	—	COMPLETED	2020-07-30	NCT04088721
Emergo Therapeutics, Inc.	Norketotifen	—	COMPLETED	2019-05-18	NCT03887026
Regeneron	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2019-05-14	NCT03558997
AOBiome LLC	B244 suspension	—	COMPLETED	2018-12-21	NCT03290248
Anergis	AllerT	—	COMPLETED	2017-07	NCT02943720
HAL Allergy	SUBLIVAC FIX Phleum Prat.	—	COMPLETED	2016-10	NCT02556801
Allergy Therapeutics	Grass MATA MPL (0.5ml) 5100SU	—	COMPLETED	2016-05-05	NCT02582073
3E Therapeutics Corporation	Nasapaque Nasal Solution	—	COMPLETED	2015-07	NCT02377895
Circassia Limited	Grass-SPIRE	—	COMPLETED	2015-03	NCT02161107
Glenmark Pharmaceuticals Ltd. India	GSP 301-1 NS (QD)	—	COMPLETED	2015-02	NCT02318303
Sun Pharma Advanced Research Company Limited	SPARC1310 I	—	COMPLETED	2014-12	NCT01940146
Circassia Limited	Ragweed-SPIRE	—	COMPLETED	2014-10	NCT02061709
Circassia Limited	Ragweed-SPIRE	—	COMPLETED	2014-10	NCT02061670
GSK	GSK2245035	—	COMPLETED	2014-08	NCT01788813
Glenmark Pharmaceuticals Ltd. India	Molo 1 (also referred as GSP 301-2 NS)	—	COMPLETED	2014-02-28	NCT03444506
Ono Pharmaceutical Co., Ltd.	Cetirizine	—	COMPLETED	2014-02	NCT01748344
Laboratorios Leti, S.L.	Prick test Dermatophagoides pteronyssinus allergen extract	—	COMPLETED	2014-01	NCT01821716
BioTech Tools S.A.	gpASIT+TM	—	COMPLETED	2013-12	NCT02156791
Novartis	QAW039	—	COMPLETED	2013-10	NCT01804400
Anergis	AllerT low dose	—	COMPLETED	2013-09	NCT01720251
ALK-Abelló A/S	SLITone ULTRA HDM immunotherapy	—	COMPLETED	2013-08	NCT01728298
HAL Allergy	SUBLIVAC FIX phleum prat.	—	COMPLETED	2013-05	NCT01682070
HAL Allergy	PURETHAL Mites 6,667 AU/ml	—	COMPLETED	2013-05	NCT01438463
Leti Pharma GmbH	Depigoid Phleum	—	COMPLETED	2013-04	NCT01634958
HAL Allergy	SUBLIVAC FIX Birch	—	COMPLETED	2013-03	NCT01639768
Bausch & Lomb Incorporated	Bepotastine besilate	H1-receptor	COMPLETED	2013-02	NCT01753739
BioTech Tools S.A.	gpASIT+TM	—	COMPLETED	2013-01	NCT01506375
Sun Pharma Advanced Research Company Limited	SPARC1203	—	COMPLETED	2012-11	NCT01614691
Shionogi	S-555739 Dose 1	—	COMPLETED	2012-11	NCT01651871
Bausch & Lomb Incorporated	Bepotastine besilate formulation	—	COMPLETED	2012-08	NCT01578278
Stallergenes Greer	100 IR house dust mites allergen extract tablet	—	COMPLETED	2012-03	NCT01527188
Teva Pharmaceuticals USA	Mometasone furoate	Glucocorticoid receptor	COMPLETED	2012-01	NCT01523236
Novartis	VAK694; Alutard Avanz SQ	—	COMPLETED	2011-10	NCT01018693
BioTech Tools S.A.	gpASIT+TM	—	COMPLETED	2011-10	NCT01308021
Palau Pharma S.L.U.	UR-63325	—	COMPLETED	2011-03	NCT01260753
Novartis	VAK694	—	COMPLETED	2011-02	NCT00929968
Bausch & Lomb Incorporated	Bepotastine Besilate Nasal Spray 2% Twice a day	—	COMPLETED	2011-02	NCT01277341
Idorsia Pharmaceuticals Ltd.	ACT-129968	—	COMPLETED	2011-02	NCT01241214
Leti Pharma GmbH	Allergoid, allergenic extract of 100% Birch	—	COMPLETED	2011-02	NCT01144429
AstraZeneca	AZD8848	—	COMPLETED	2010-12	NCT01185080
Respivert Ltd	RV568	—	COMPLETED	2010-11	NCT01230619
Magna Pharmaceuticals, Inc.	STAHIST	—	COMPLETED	2010-10	NCT01171664
Nuvo Research GmbH	WF10	—	COMPLETED	2010-09	NCT01586468
Afexa Life Sciences Inc	COLD-fX	—	COMPLETED	2010-09	NCT00726401
Bausch & Lomb Incorporated	bepotastine besilate nasal product - low dose	—	COMPLETED	2010-08	NCT01222299
HAL Allergy	PURETHAL Mites 20,000 AUeq/ml	—	COMPLETED	2010-08	NCT00973453
Novartis	QAV680 + Cetirizine	—	COMPLETED	2010-07-28	NCT01103050
Pfizer	PF-03654764	—	COMPLETED	2010-05	NCT01033396
Capnia, Inc.	Nasal CO2	—	COMPLETED	2009-10	NCT00917020
Capnia, Inc.	Nasal CO2	—	COMPLETED	2009-10	NCT00917111
Teva Branded Pharmaceutical Products R&D, Inc.	Beclomethasone dipropionate HFA Nasal Aerosol	—	COMPLETED	2009-05	NCT00854360
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	JNJ-39220675	—	COMPLETED	2009-02	NCT00804687
Novartis	QAV680	—	COMPLETED	2008-12	NCT00784732
Dart NeuroScience, LLC	BLX-028914	—	COMPLETED	2008-12	NCT00758446
Alcon Research	Olopatadine Hydrochloride Nasal Spray 0.6%	—	COMPLETED	2008-12	NCT00794144
Capnia, Inc.	Nasal CO2	—	COMPLETED	2008-10	NCT00688441
GSK	GSK1004723 (200mg)	—	COMPLETED	2008-08	NCT00824356
Merck	SCH 900538	—	COMPLETED	2008-07	NCT00673062
Oxagen Ltd	OC000459	—	COMPLETED	2008-07	NCT00697281
Ligand Pharmaceuticals	Budesonide + Azelastine	—	COMPLETED	2008-05	NCT00940953
GSK	GSK256066	—	COMPLETED	2008-05	NCT00612118
Capnia, Inc.	Nasal Carbon Dioxide	—	COMPLETED	2008-05	NCT00638755
Max Zeller Soehne AG	Desloratadin	—	COMPLETED	2008-04	NCT00862225
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	JNJ-17166864	—	COMPLETED	2008-02	NCT00604123
Laboratorios Leti, S.L.	Depigoid® (500 DPP/ml)	—	TERMINATED	2012-07	NCT01591343
Anergis	AllerT SC	—	TERMINATED	2009-03	NCT01728519
ALK-Abelló A/S	OSIRIS	—	TERMINATED	—	NCT01240954

Showing 38 of 38 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
AJU Pharm Co., Ltd.	AJU-R713	—	NOT YET RECRUITING	2025-12	NCT07231861
Anhui Palo Alto Pharmaceuticals, Inc.	PA9159 nasal spray solution, 80 μg one day treatment	—	COMPLETED	2025-06-09	NCT07345442
Inimmune Corporation	INI-2004	—	COMPLETED	2024-09-05	NCT06038279
Humanis Saglık Anonim Sirketi	Azelastine Hydrochloride/ Fluticasone propionate nasal spray	—	COMPLETED	2023-04-26	NCT06180083
H. Lundbeck A/S	Lu AG09222	—	COMPLETED	2022-07-12	NCT05126316
Anhui Palo Alto Pharmaceuticals, Inc.	PA9159 nasal spray solution, 10 μg one day treatment	—	COMPLETED	2022-01-05	NCT05170763
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	CSPCHA115 100 mg; Matching placebo 100 mg	—	COMPLETED	2020-06-01	NCT04161547
Tanabe Pharma Corporation	MT-2990	—	COMPLETED	2018-12-27	NCT03570957
Allergy Therapeutics	Grass MATA MPL	—	COMPLETED	2017-04-27	NCT03931993
Allergy Therapeutics	Grass MATA MPL 10200	—	COMPLETED	2015-10	NCT02557633
Xencor, Inc.	XmAb7195	—	COMPLETED	2015-09-21	NCT02148744
Merck	MK-8237	—	COMPLETED	2015-07-20	NCT01852825
Pfizer	IGE-1	—	COMPLETED	2015-06	NCT01723254
Immunomic Therapeutics, Inc.	CryJ2-DNA-LAMP plasmid vaccine by intradermal injection	—	COMPLETED	2015-03	NCT02146781
Johnson & Johnson	Esketamine	—	COMPLETED	2014-10	NCT02154334
PharmaKing	Montelukast	—	COMPLETED	2014-01	NCT02029313
Mylan Pharmaceuticals Inc	Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act.	—	COMPLETED	2013-10	NCT02109185
Stallergenes Greer	500 IR house dust mites allergen extract tablet	—	COMPLETED	2013-09	NCT01919554
MedImmune LLC	Omalizumab	Anti-IgE [EPC]	COMPLETED	2013-06	NCT01544348
Sumitomo Pharma America, Inc.	ciclesonide nasal aerosol	—	COMPLETED	2011-08	NCT01371786
Roche	MEMP1972A	—	COMPLETED	2011-04	NCT01160861
MEDA Pharma GmbH & Co. KG	Azelastine, Fluticasone	—	COMPLETED	2010-10	NCT01194622
MEDA Pharma GmbH & Co. KG	Azelastine, Fluticasone	—	COMPLETED	2010-10	NCT01190852
Gilead	CAL-263	—	COMPLETED	2010-04	NCT01066611
Pfizer	Ibuprofen	Nonsteroidal Anti-inflammatory Drug [EPC]	COMPLETED	2010-04	NCT01064726
Procter and Gamble	Doxylamine Succinate USP	—	COMPLETED	2009-06	NCT00796315
Merck	prednisone	Corticosteroid [EPC]	COMPLETED	2009-05-07	NCT00828061
Teva Branded Pharmaceutical Products R&D, Inc.	BDP HFA Nasal Aerosol	—	COMPLETED	2009-04	NCT01537692
Gilead	CAL-101	—	COMPLETED	2009-03	NCT00836914
AstraZeneca	AZD8848	—	COMPLETED	2009-03	NCT00770003
Johnson & Johnson Consumer and Personal Products Worldwide	diphenhydramine HCl	—	COMPLETED	2008-11	NCT00762749
AstraZeneca	AZD8848	—	COMPLETED	2008-05	NCT00688779
Anergis	Histamine	—	COMPLETED	2008-03	NCT01719133
Sumitomo Pharma Co., Ltd.	DSP-3025	—	COMPLETED	—	NCT00925678
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	JNJ38224342	—	COMPLETED	—	NCT01054352
Novartis	Mometasone + Azelastine	—	TERMINATED	2023-09-08	NCT05887843
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQC3564 tablets	—	TERMINATED	2023-05-09	NCT05607446
Woodmont Pharmaceuticals, Inc.	Dose Level 1	—	TERMINATED	2017-04-29	NCT03038971

Novel Allergic Rhinitis Drugs by Company (New molecular entities)

1 company has an FDA-approved novel drug for Allergic Rhinitis.

AZURITY 1 drug

OMNARIS

CICLESONIDE

NDA 2006

Reformulations (10 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.